The shifts in the automaker’s electric vehicle strategy will cost the Detroit automaker up to $1.9 billion in expenses and write-downs.
Continue readingCategory Archives: Uncategorized
Delta chief operations officer departing for another company after just over a year on the job
Delta’s COO Mike Spanos, a company outsider, was hired in May 2023.
Continue readingClassic car sales stall in Monterey auctions as new generation takes charge
The average sale price was $476,965, down slightly from last year’s average of $477,866.
Continue readingBoeing Starliner returning empty as NASA turns to SpaceX to bring astronauts back from ISS
Boeing will return its capsule from the International Space Station without the NASA astronauts that Starliner delivered to orbit.
Continue readingBronfman’s Paramount bid could keep Shari Redstone involved at the company
Edgar Bronfman Jr. is open to having Shari Redstone remain involved at Paramount if the special committee accepts his consortium’s bid for a controlling stake.
Continue readingU.S. will again offer free at-home Covid tests starting in late September
Americans will soon be able to use COVIDtests.gov to request four free tests, Biden administration officials said.
Continue readingMavericks, Pelicans games are leaving their local sports networks ahead of NBA season
The Dallas Mavericks and New Orleans Pelicans terminated their deals with Diamond Sports ahead of the NBA season, which begins in October.
Continue readingNBCUniversal is pinning Peacock’s streaming success on its $2.45 billion per year NBA deal
NBC Sports is banking on the long-term success of Peacock and sports as the linchpin to making its $2.45 billion bid for the NBA profitable.
Continue readingLockheed Martin to take struggling spacecraft manufacturer Terran Orbital private in $450 million deal
Lockheed Martin is buying Terran Orbital, the company announced Thursday.
Continue readingWhite House says negotiated prices for Medicare drugs will save U.S. $6 billion, beneficiaries $1.5 billion in first year
It is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but is strongly opposed by drugmakers.
Continue reading